Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunization
New findings from S.T. Duggan and co-researchers in the area of immunization described
April 29th, 2009
"The Japanese encephalitis vaccine IC-51 (IXIARO (R)) is an inactivated virus (strain SA(14)-14-2) that is manufactured in cultured Vero cells and is currently being developed for preventive vaccination against the Japanese encephalitis virus. Administration of IXIARO (R) as a two-dose treatment in healthy adults provided high levels of sero-protection against Japanese encephalitis virus," scientists writing in the journal Drugs report. "Immune responses at 56 days post-vaccination, including seroconversion rates and geometric mean titres, were noninferior to those seen with a currently available licensed vaccine. Seroprotection was achieved 1 week after second...
Source: Vaccine Weekly (2009-04-29)
|
